Guggenheim Lowers Valneva (NASDAQ:VALN) Price Target to $13.00

Key Points

• Guggenheim has lowered its price target for Valneva's stock from $14.00 to $13.00, while maintaining a "buy" rating, indicating a potential upside of 55.97% from the previous closing price.
• Other brokerages have also issued varying ratings, with Jefferies Financial Group setting a price target of $14.00 and HC Wainwright issuing a target of $18.00, reflecting a consensus rating of "buy".
• Valneva reported a loss of ($0.16) earnings per share for the quarter, exceeding analyst expectations, and had a revenue of $54.84 million compared to estimates of $46.28 million.

Valneva (NASDAQ:VALN - Get Free Report) had its price objective decreased by stock analysts at Guggenheim from $14.00 to $13.00 in a report released on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. Guggenheim's price objective indicates a potential upside of 45.41% from the company's previous close.

Several other research analysts have also issued reports on the company. Wall Street Zen upgraded Valneva to a "hold" rating in a research report on Saturday, September 6th. HC Wainwright restated a "buy" rating and issued a $18.00 price target on shares of Valneva in a research report on Monday, August 25th. Finally, Jefferies Financial Group set a $14.00 price target on Valneva and gave the stock a "buy" rating in a research report on Monday, August 25th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $15.00.

Valneva Trading Down 2.6%

Shares of NASDAQ VALN traded down $0.24 during midday trading on Monday, hitting $8.94. The stock had a trading volume of 40,127 shares, compared to its average volume of 127,130. The company's 50-day simple moving average is $8.35 and its 200 day simple moving average is $7.13. The firm has a market cap of $768.21 million, a P/E ratio of -9.12 and a beta of 1.79. Valneva has a fifty-two week low of $3.62 and a fifty-two week high of $12.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.27 and a quick ratio of 1.77.

Valneva (NASDAQ:VALN - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. The company had revenue of $54.84 million during the quarter, compared to analysts' expectations of $46.28 million. Valneva had a negative return on equity of 34.78% and a negative net margin of 33.87%. Research analysts anticipate that Valneva will post 0.13 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marex Group plc bought a new position in Valneva during the second quarter worth about $64,000. Frazier Life Sciences Management L.P. acquired a new stake in shares of Valneva in the 2nd quarter valued at about $8,240,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Valneva in the 1st quarter valued at about $94,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.